These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20109138)

  • 41. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
    Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
    J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
    Speiser DE; Romero P
    Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Specificity in cancer immunotherapy.
    Schietinger A; Philip M; Schreiber H
    Semin Immunol; 2008 Oct; 20(5):276-85. PubMed ID: 18684640
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor vaccines and beyond.
    Melenhorst JJ; Barrett AJ
    Cytotherapy; 2011 Jan; 13(1):8-18. PubMed ID: 21067312
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic cancer vaccine: building the future from lessons of the past.
    Tran T; Blanc C; Granier C; Saldmann A; Tanchot C; Tartour E
    Semin Immunopathol; 2019 Jan; 41(1):69-85. PubMed ID: 29978248
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multiple-purpose immunotherapy for cancer.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Biomed Pharmacother; 2015 Dec; 76():24-9. PubMed ID: 26653546
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cancer neoantigen: Boosting immunotherapy.
    Xu P; Luo H; Kong Y; Lai WF; Cui L; Zhu X
    Biomed Pharmacother; 2020 Nov; 131():110640. PubMed ID: 32836075
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines.
    Grau M; Walker PR; Derouazi M
    Cell Mol Life Sci; 2018 Aug; 75(16):2887-2896. PubMed ID: 29508006
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dendritic cells as vectors for immunotherapy of cancer.
    Paczesny S; Ueno H; Fay J; Banchereau J; Palucka AK
    Semin Cancer Biol; 2003 Dec; 13(6):439-47. PubMed ID: 15001163
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.
    Gjerstorff MF; Burns J; Ditzel HJ
    Expert Opin Biol Ther; 2010 Jul; 10(7):1061-75. PubMed ID: 20420535
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting inhibitory pathways in cancer immunotherapy.
    Lasaro MO; Ertl HC
    Curr Opin Immunol; 2010 Jun; 22(3):385-90. PubMed ID: 20466529
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Xenogene vaccination in the therapy of cancer.
    Cavallo F; Aurisicchio L; Mancini R; Ciliberto G
    Expert Opin Biol Ther; 2014 Oct; 14(10):1427-42. PubMed ID: 25023219
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cancer vaccines and immunotherapy.
    Dermime S; Armstrong A; Hawkins RE; Stern PL
    Br Med Bull; 2002; 62():149-62. PubMed ID: 12176857
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of DNA and mRNA vaccines against cancer.
    Jahanafrooz Z; Baradaran B; Mosafer J; Hashemzaei M; Rezaei T; Mokhtarzadeh A; Hamblin MR
    Drug Discov Today; 2020 Mar; 25(3):552-560. PubMed ID: 31843577
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cancer Immunotherapy: Priming the Host Immune Response with Live Attenuated
    Hernández-Luna MA; Luria-Pérez R
    J Immunol Res; 2018; 2018():2984247. PubMed ID: 30302344
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Applications of peptide mimetics in cancer.
    Apostolopoulos V; Matsoukas J; Plebanski M; Mavromoustakos T
    Curr Med Chem; 2002 Feb; 9(4):411-20. PubMed ID: 11945117
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Promising approaches in cancer immunotherapy.
    Taefehshokr N; Baradaran B; Baghbanzadeh A; Taefehshokr S
    Immunobiology; 2020 Mar; 225(2):151875. PubMed ID: 31812343
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.
    Obeid J; Hu Y; Slingluff CL
    Semin Oncol; 2015 Aug; 42(4):549-61. PubMed ID: 26320060
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.